Page 15 - Flipbook
P. 15
Neoadjuvant therapy: strong scientific rationale and works in
melanoma – why not RCC?
Landmark 2-year EFS: 72% v. 49%
Sapna P. Patel, MD Content of this presentation is copyright and responsibility of the author. Permission is required for re-use.
Patel et al. ESMO 2022
